Company news

Altimmune, Inc. news in 2026

Altimmune, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution

October 27, 2026

Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026

October 19, 2026

Altimmune to Participate in Stifel Cardiometabolic Forum

September 23, 2026

Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference

September 3, 2026

Altimmune Announces Second Quarter 2026 Financial Results and Business Update

August 12, 2026

Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

August 5, 2026

Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH

August 3, 2026

Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder

July 28, 2026

Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026

May 28, 2026

New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026

May 27, 2026

Altimmune Announces First Quarter 2026 Financial Results and Business Update

May 13, 2026

Altimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026

May 13, 2026

Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026

May 6, 2026

Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities

April 27, 2026

Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities

April 22, 2026

Altimmune Announces Proposed Underwritten Public Offering of Securities

April 22, 2026

Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates

March 4, 2026

Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026

February 26, 2026

Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock

January 29, 2026

Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock

January 27, 2026

Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH

January 5, 2026

Calls in 2026

Decks in 2026